| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | 0 |
Sells | $388,115 | 10 | 100 |
| Powl Brian T. | Chief Commercial Officer | 0 | $0 | 1 | $12,461 | $-12,461 |
| Burrows Francis | Chief Scientific Officer | 0 | $0 | 1 | $17,051 | $-17,051 |
| FORD KATHLEEN | Chief Operating Officer | 0 | $0 | 3 | $32,514 | $-32,514 |
| DOYLE THOMAS JAMES | SVP, Finance & Accounting | 0 | $0 | 1 | $38,958 | $-38,958 |
| Leoni Mollie | Chief Medical Officer | 0 | $0 | 1 | $39,068 | $-39,068 |
| Bair Teresa Brophy | Chief Legal Officer | 0 | $0 | 2 | $66,607 | $-66,607 |
| Hasnain Faheem | director | 0 | $0 | 1 | $181,456 | $-181,456 |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Kura Oncology, Inc. have bought $0 and sold $388,115 worth of Kura Oncology, Inc. stock.
On average, over the past 5 years, insiders at Kura Oncology, Inc. have bought $575,000 and sold $7.09M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 50,000 shares for transaction amount of $575,000 was made by Malley Thomas (director) on 2023‑06‑16.
| 2025-05-19 | Sale | Bair Teresa Brophy | Chief Legal Officer | 1,559 0.0017% | $5.96 | $9,292 | -1.84% | |
| 2025-05-19 | Sale | FORD KATHLEEN | Chief Operating Officer | 1,558 0.0018% | $6.28 | $9,777 | -1.84% | |
| 2025-03-21 | Sale | Hasnain Faheem | director | 22,682 0.0287% | $8.00 | $181,456 | -21.30% | |
| 2025-01-28 | Sale | Bair Teresa Brophy | Chief Legal Officer | 7,281 0.0094% | $7.87 | $57,315 | -17.05% | |
| 2025-01-28 | Sale | Leoni Mollie | Chief Medical Officer | 4,963 0.0064% | $7.87 | $39,068 | -17.05% | |
| 2025-01-28 | Sale | DOYLE THOMAS JAMES | SVP, Finance & Accounting | 4,949 0.0064% | $7.87 | $38,958 | -17.05% | |
| 2025-01-28 | Sale | Powl Brian T. | Chief Commercial Officer | 1,583 0.0021% | $7.87 | $12,461 | -17.05% | |
| 2025-01-28 | Sale | FORD KATHLEEN | Chief Operating Officer | 1,817 0.0024% | $7.87 | $14,303 | -17.05% | |
| 2025-01-28 | Sale | Burrows Francis | Chief Scientific Officer | 2,166 0.0028% | $7.87 | $17,051 | -17.05% | |
| 2024-11-18 | Sale | FORD KATHLEEN | Chief Operating Officer | 526 0.0007% | $16.03 | $8,434 | -54.86% | |
| 2024-05-20 | Sale | Bair Teresa Brophy | Chief Legal Officer | 2,615 0.0034% | $22.15 | $57,916 | -28.06% | |
| 2024-01-30 | Sale | DALE STEPHEN | Chief Medical Officer | 4,825 0.0067% | $21.55 | $103,980 | -4.22% | |
| 2024-01-29 | Sale | Bair Teresa Brophy | Chief Legal Officer | 2,053 0.0027% | $17.80 | $36,544 | +7.47% | |
| 2024-01-29 | Sale | DOYLE THOMAS JAMES | SVP, Finance & Accounting | 2,318 0.003% | $17.80 | $41,262 | +7.47% | |
| 2024-01-29 | Sale | DALE STEPHEN | Chief Medical Officer | 7,158 0.0093% | $17.80 | $127,416 | +7.47% | |
| 2024-01-29 | Sale | FORD KATHLEEN | Chief Operating Officer | 1,496 0.0019% | $17.80 | $26,630 | +7.47% | |
| 2024-01-24 | Sale | WILSON TROY EDWARD | President and CEO | 84,107 0.1166% | $20.23 | $1.7M | +1.94% | |
| 2023-06-16 | Malley Thomas | director | 50,000 0.0781% | $11.50 | $575,000 | +12.69% | ||
| 2023-01-27 | Sale | DALE STEPHEN | Chief Medical Officer | 9,225 0.0138% | $13.88 | $128,033 | -19.32% | |
| 2023-01-27 | Sale | FORD KATHLEEN | Chief Operating Officer | 1,821 0.0027% | $13.89 | $25,294 | -19.32% |
| Bair Teresa Brophy | Chief Legal Officer | 107948 0.1247% | $688,708.24 | 0 | 4 | |
| DOYLE THOMAS JAMES | SVP, Finance & Accounting | 88193 0.1019% | $562,671.34 | 0 | 3 | |
| Leoni Mollie | Chief Medical Officer | 88253 0.1019% | $563,054.14 | 0 | 1 | |
| Powl Brian T. | Chief Commercial Officer | 59667 0.0689% | $380,675.46 | 0 | 1 | |
| Hasnain Faheem | director | 23983 0.0277% | $153,011.54 | 0 | 1 | |
| FORD KATHLEEN | Chief Operating Officer | 21367 0.0247% | $136,321.46 | 0 | 10 | |
| Burrows Francis | Chief Scientific Officer | 20705 0.0239% | $132,097.90 | 0 | 1 | |
| EcoR1 Capital Fund Qualified, L.P. | 10 percent owner | 4408097 5.0917% | $28.12M | 8 | 1 | +14.44% |
| GUALBERTO ANTONIO | Head of Development & CMO | 339973 0.3927% | $2.17M | 0 | 1 | |
| Malley Thomas | director | 139557 0.1612% | $890,373.66 | 2 | 0 | <0.0001% |
| DALE STEPHEN | Chief Medical Officer | 38817 0.0448% | $247,652.46 | 0 | 3 | |
| FLOWERS KIRSTEN | CCO & Chief Strategy Officer | 20605 0.0238% | $131,459.90 | 0 | 1 | |
| WILSON TROY EDWARD | President and CEO | 559 0.0006% | $3,566.42 | 0 | 13 | |
| GRASSO MARC | CFO, CBO | 0 0% | $0 | 0 | 4 |
$26,818,588 | 97 | 5.39% | $464.46M | |
$587,109,125 | 90 | 3.17% | $543.13M | |
$860,541,348 | 82 | -5.10% | $468.5M | |
$56,593,094 | 24 | 46.48% | $460.27M | |
$24,857,912 | 21 | -35.40% | $542.03M | |
$6,280,187 | 19 | 6.80% | $571.74M | |
$49,750,490 | 17 | 37.19% | $581.55M | |
$18,455,830 | 13 | 24.59% | $582.52M | |
$133,809,976 | 13 | 31.29% | $554M | |
$92,357,691 | 12 | 87.24% | $588.52M | |
Kura Oncology, Inc. (KURA) | $11,541,901 | 10 | 8.07% | $552.35M |
$3,073,199 | 10 | 16.77% | $524.83M | |
$91,721,700 | 9 | -13.73% | $538.39M | |
$94,000,000 | 7 | -20.84% | $530.43M | |
$73,280,625 | 6 | -41.09% | $580.7M | |
$3,200,000 | 5 | -11.36% | $624.06M | |
$1,746,565 | 4 | -29.05% | $561.91M | |
$3,250,000 | 1 | -44.91% | $476.26M | |
$13,900 | 1 | -39.25% | $599.48M |
| Increased Positions | 95 | +42.04% | 15M | +18.64% |
| Decreased Positions | 97 | -42.92% | 13M | -16.5% |
| New Positions | 36 | New | 3M | New |
| Sold Out Positions | 38 | Sold Out | 6M | Sold Out |
| Total Postitions | 224 | -0.88% | 82M | +2.14% |
| Blackrock, Inc. | $52,909.00 | 9.4% | 8.18M | +243,542 | +3.07% | 2025-03-31 |
| Armistice Capital, Llc | $37,526.00 | 6.67% | 5.8M | +3M | +118.21% | 2024-12-31 |
| Suvretta Capital Management, Llc | $32,845.00 | 5.84% | 5.08M | -3M | -33.66% | 2024-12-31 |
| Vanguard Group Inc | $31,178.00 | 5.54% | 4.82M | +615,211 | +14.63% | 2024-12-31 |
| Ra Capital Management, L.P. | $28,798.00 | 5.12% | 4.45M | +4M | New | 2024-12-31 |
| Ecor1 Capital, Llc | $23,016.00 | 4.09% | 3.56M | -2M | -38.74% | 2024-12-31 |
| State Street Corp | $21,645.00 | 3.85% | 3.35M | +676,618 | +25.35% | 2024-12-31 |
| Morgan Stanley | $21,184.00 | 3.76% | 3.27M | +2M | +171.33% | 2024-12-31 |
| Bvf Inc/Il | $16,612.00 | 2.95% | 2.57M | -804,292 | -23.85% | 2024-12-31 |
| Millennium Management Llc | $15,315.00 | 2.72% | 2.37M | +2M | +180.07% | 2024-12-31 |